Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Carcinoma, Renal Cell 7Sarcoma 5Melanoma 5Lymphoma, Non-Hodgkin 5Prostatic Neoplasms 4Ovarian Neoplasms 4Neoplasms 4Endometrial Neoplasms 4Carcinoma, Hepatocellular 4Neoplasm Metastasis 3Multiple Myeloma 3Lymphoma, Large B-Cell, Diffuse 3Leukemia, Myeloid, Acute 3Kidney Neoplasms 3Glioblastoma 3Squamous Cell Carcinoma of Head and Neck 2Rhabdomyosarcoma 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Osteosarcoma 2Neuroectodermal Tumors, Primitive, Peripheral 2Neuroblastoma 2Lymphoma, Mantle-Cell 2Liver Neoplasms 2Leukemia, Lymphocytic, Chronic, B-Cell 2Hodgkin Disease 2Fallopian Tube Neoplasms 2Congenital Abnormalities 2Breast Neoplasms 2Waldenstrom Macroglobulinemia 1Uterine Cervical Neoplasms 1

Interventions

Ifosfamide 4Doxorubicin 4Imatinib Mesylate 3Filgrastim 3brostallicin 2Vincristine 2Sunitinib 2Radiotherapy 2Radiation Dose Hypofractionation 2Etoposide 2Dactinomycin 2Cyclophosphamide 2Carboplatin 2temsirolimus 1soblidotin 1saracatinib 1romidepsin 1reolysin 1perifosine 1pazopanib 1exatecan 1etoposide phosphate 1cixutumumab 1Trabectedin 1Topotecan 1Thiotepa 1Temozolomide 1Surgical Procedures, Operative 1Sirolimus 1Razoxane 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Fibrosarcoma × temsirolimus × Clear all
NCT01614795 2018-12-11

Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma

National Cancer Institute (NCI)

Phase 2 Completed
46 enrolled 13 charts
Sarcoma

Fibrosarcoma, Hemangiosarcoma, Liposarcoma, Rhabdomyosarcoma, Sarcoma, Osteosarcoma, Neuroectodermal Tumors, Primitive, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡